29-11-2022 Comments (0)Print
27-09-2021
14-11-2016
12-11-2015
28-11-2022
28-11-2022
25-11-2022
The recent approval of Hua Medicine’s (HK: 2552) first-in-class diabetes drug – HuaTangNing (dorzagliatin tablets, HMS5552) – in China, in collaboration with Germany’s Bayer (BAYN: DE), puts an end to a decade-long wait for molecules with a new mechanism of action, as well as marked the initiation of international partnerships by domestic companies for T2D market in China, says data and analytics company GlobalData.
China has shown the highest prevalence of diagnosed T2D cases among the 16 major markets (16MM*), with a higher prevalence in women (6.7%) than in men (6%) in 2022. The population between 40 to 80 years is most expected to see a rise in diagnosed cases at an annual growth rate of 3.3% from 6 million in 2022 to 6.7 million in 2028, according to GlobalData’s Pharmaceutical Intelligence Center.
GlobalData pharma analyst Atulana Dey commented: “Over the past few decades, China has witnessed a steep rise in T2D patients, majorly owing to a greater percentage of geriatric population, sedentary lifestyle and poor living choices like smoking and excessive consumption of alcohol that elevates the body’s sugar levels.”
The current treatment options for T2D in China are well established with the popular class of drugs being DPP-4 inhibitors, GLP-1 analogs and recombinant proteins like insulins. Global giants such as Bayer, Boehringer Ingelheim, Novo Nordisk (NOV: N), Eli Lilly (NYSE: LLY), AstraZeneca (LSE: AZN), Xian-Janssen, Merck & Co (NYSE: MRK), Novartis (NOVN: VX), Tianjin Tanabe, Takeda (TYO: 4502) and Hua rule the present anti-diabetic market in China.
“Chinese firms are quickly catching up with the majority of the late-stage pipeline drugs being developed by domestic companies like Sihuan Pharmaceutical, Tonghua Dongbao, ConjuChem, Shanghai Innogen, CSPC Pharmaceutical and Jiangsu HengRui Medicine,” Ms Dey noted.
Against this backdrop, Hua’s first-in-class glucokinase activator (GKA) dorzagliatin, an anti-diabetic drug with a new mechanism of action, was approved by NMDA in October 2022 for uncontrolled T2D in China. Hua’s partnership with Bayer for the commercialization of the drug and with state-owned Sinopharm for local distribution might be a step towards setting the trend.
Ms Dey concluded: “With T2D being the major growth driver for China’s pharmaceutical market along with a rapid rise in the number of diagnosed cases, global companies should take this opportunity to forge strategic partnerships and commercial alliances with the domestic companies not only to create more visibility and access for the home-grown products to the population but also gain an advantage by utilizing the local resources to build, commercialize and market the products in China.
BayerChinaDealsDiabetesdorzagliatinHua MedicineMarkets & MarketingPharmaceuticalResearch
Diabetes, Type 2, Prevalence, Partnerships, Commercialization, China, Hua Medicines, Bayer, Dorzagliatin, Treatments, GlobalData
Key Phase III trial shows dorzagliatin improves early phase insulin secretion
27-09-2021
Over 170 drugs under research to deal with the diabetes challenges; China report
14-11-2016
China needs national disease awareness program to deal with diabetes crisis
12-11-2015
Login to add a comment
There are no comments yet. Be the first and leave a response!
A clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders.
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.
The Pharma Letter
39 to 43 Putney High Street
Putney
London
SW15 1SP
For trial and subscription enquiries please email [email protected]
For editorial enquiries, press releases and events please email [email protected]
For all other queries please email [email protected]
Agile web development by Byte9 
The Pharma Letter offers breaking news and insight for people with a professional interest in the pharma and biotech industries.
As a member of the AstraZeneca group, you are entitled to a free three-month subscription.
To claim your full-access subscription, register for a personal account.
You can also read our mission.
Back to top